Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 17/20 | 0.60 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.55 |
| ▸ | FPR3 | P25089 | 1/20 | 0.54 |
| ▸ | GPR65 | Q8IYL9 | 1/20 | 0.54 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.54 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6245342 | 0.94 | CCR1 (0.56) | CCR1PTGDR2FPR3GPR65GPR35 | |
| SCHEMBL6248195 | 0.94 | CCR1 (0.52) | CCR1PTGDR2FPR3GPR65GPR35 | |
| SCHEMBL6244865 | 0.92 | CCR1 (0.62) | CCR1PTGDR2FPR3GPR65GPR35 | |
| SCHEMBL6244867 | 0.92 | CCR1 (0.62) | CCR1PTGDR2FPR3GPR65GPR35 | |
| SCHEMBL6246929 | 0.91 | CCR1 (0.55) | CCR1PTGDR2FPR3GPR65GPR35 | |
| SCHEMBL6250541 | 0.88 | CCR1 (0.66) | CCR1PTGDR2FPR3GPR65GPR35 | |
| SCHEMBL6247113 | 0.87 | CCR1 (0.54) | CCR1PTGDR2FPR3GPR65GPR35 | |
| SCHEMBL6248241 | 0.87 | PTGDR2 (0.67) | CCR1PTGDR2FPR3GPR65GPR35 | |
| SCHEMBL6248240 | 0.87 | PTGDR2 (0.67) | CCR1PTGDR2FPR3GPR65GPR35 | |
| SCHEMBL6246845 | 0.86 | CCR1 (0.58) | CCR1PTGDR2FPR3GPR65GPR35 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6974817-B2 | CCR1 receptor antagonists; inhibitors of MIP-1 alpha (CCL3) binding to its receptor CCR1 found on inflammatory and immunomodulatory cells; macrophage inflammatory protein (MIP) | PFIZER INC. (US) | 2005-12-13 | — | — | US | claimed |
| EP-1558258-A1 | USE OF PIPERAZINE SULFONIC ACID DERIVATIVES AS CCR1 ANTAGONISTS FOR THE TREATMENT OF FIBROSIS, ALZHEIMER DISEASE AND OTHER DISORDERS | Pfizer Products Inc. (US) | 2005-08-03 | — | — | EP | claimed |
| EP-1430041-A2 | NOVEL SULFONIC ACID DERIVATIVES | Pfizer Products Inc. (US) | 2004-06-23 | — | — | EP | claimed |
| US-20040116441-A1 | Methods of using sulfonic acid derivatives | PFIZER INC | 2004-06-17 | — | — | US | claimed |
| WO-2004039377-A1 | USE OF PIPERAZINE SULFONIC ACID DERIVATIVES AS CCR1 ANTAGONISTS FOR THE TREATMENT OF FIBROSIS, ALZHEIMER DISEASE AND OTHER DISORDERS | PFIZER PRODUCTS INC. (US) | 2004-05-13 | — | — | WO | claimed |
| US-20030083335-A1 | Novel sulfonic acid derivatives | HAYWARD MATTHEW M (US) | 2003-05-01 | — | — | US | claimed |
| WO-2002102787-A2 | NOVEL SULFONIC ACID DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2002-12-27 | — | — | WO | claimed |
| US-6974817-B2 | CCR1 receptor antagonists; inhibitors of MIP-1 alpha (CCL3) binding to its receptor CCR1 found on inflammatory and immunomodulatory cells; macrophage inflammatory protein (MIP) | PFIZER INC. (US) | 2005-12-13 | — | — | US | disclosed |
| US-20050250790-A1 | Novel sulfonic acid derivatives | PFIZER INC | 2005-11-10 | — | — | US | disclosed |
| EP-1558258-A1 | USE OF PIPERAZINE SULFONIC ACID DERIVATIVES AS CCR1 ANTAGONISTS FOR THE TREATMENT OF FIBROSIS, ALZHEIMER DISEASE AND OTHER DISORDERS | Pfizer Products Inc. (US) | 2005-08-03 | — | — | EP | disclosed |
| EP-1430041-A2 | NOVEL SULFONIC ACID DERIVATIVES | Pfizer Products Inc. (US) | 2004-06-23 | — | — | EP | disclosed |
| US-20040116441-A1 | Methods of using sulfonic acid derivatives | PFIZER INC | 2004-06-17 | — | — | US | disclosed |
| WO-2004039377-A1 | USE OF PIPERAZINE SULFONIC ACID DERIVATIVES AS CCR1 ANTAGONISTS FOR THE TREATMENT OF FIBROSIS, ALZHEIMER DISEASE AND OTHER DISORDERS | PFIZER PRODUCTS INC. (US) | 2004-05-13 | — | — | WO | disclosed |
| US-20030083335-A1 | Novel sulfonic acid derivatives | HAYWARD MATTHEW M (US) | 2003-05-01 | — | — | US | disclosed |
| WO-2002102787-A2 | NOVEL SULFONIC ACID DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2002-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250790-A1 | Novel sulfonic acid derivatives | MSR1, MYD88, CXCR2 | CCR1 4/4885PTGDR2 808/4885FPR3 44/4885 |
| US-20030083335-A1 | Novel sulfonic acid derivatives | CCR1, MSR1, CXCR1 | CCR1 1/4885PTGDR2 1643/4885FPR3 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.